Literature DB >> 21679791

Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline).

Jerry M Zuckerman1, Fozia Qamar, Bartholomew R Bono.   

Abstract

The advanced macrolides, azithromycin and clarithromycin, and the ketolide, telithromycin, are structural analogs of erythromycin. They have several distinct advantages when compared with erythromycin, including enhanced spectrum of activity, more favorable pharmacokinetics and pharmacodynamics, once-daily administration, and improved tolerability. Clarithromycin and azithromycin are used extensively for the treatment of respiratory tract infections, sexually transmitted diseases, and Helicobacter pylori-associated peptic ulcer disease. Telithromycin is approved for the treatment of community-acquired pneumonia. Severe hepatotoxicity has been reported with the use of telithromycin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID: 21679791     DOI: 10.1016/j.mcna.2011.03.012

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  24 in total

1.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

Review 2.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

3.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.

Authors:  Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Seong Mi Moon; Su-Young Kim; Soo-Youn Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin.

Authors:  Lorenzo Villa Zapata; Philip D Hansten; John R Horn; Richard D Boyce; Sheila Gephart; Vignesh Subbian; Andrew Romero; Daniel C Malone
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

5.  A genome-wide analysis of targets of macrolide antibiotics in mammalian cells.

Authors:  Amita Gupta; Aye Ökesli-Armlovich; David Morgens; Michael C Bassik; Chaitan Khosla
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

6.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.

Authors:  Frantiescoli Dimer; Cristiane de Souza Carvalho-Wodarz; Jörg Haupenthal; Rolf Hartmann; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

Review 7.  Antibiotic treatment for the sexual partners of women with bacterial vaginosis.

Authors:  Jairo Amaya-Guio; David Andres Viveros-Carreño; Eloisa Mercedes Sierra-Barrios; Mercy Yolima Martinez-Velasquez; Carlos F Grillo-Ardila
Journal:  Cochrane Database Syst Rev       Date:  2016-10-01

8.  Cluster of macrolide-resistant Mycoplasma pneumoniae infections in Illinois in 2012.

Authors:  Victoria Tsai; Bernard B Pritzker; Maureen H Diaz; Jonas M Winchell; Lauri A Hicks; Brianna Petrone; Alvaro Benitez; Bernard J Wolff; Kenneth L Soyemi
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

9.  Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.

Authors:  Ken Nakata; Takamichi Komori; Kazuhiro Saso; Hirofumi Ota; Yoshinori Kagawa; Shunji Morita; Shingo Noura; Nobuyasu Hayashi; Mamoru Uemura; Chu Matsuda; Taroh Satoh; Tsunekazu Mizushima; Kohei Murata; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Int J Colorectal Dis       Date:  2021-08-03       Impact factor: 2.571

Review 10.  Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.

Authors:  Naina Mohamed Pakkir Maideen; Gobinath Manavalan; Kumar Balasubramanian
Journal:  Ther Adv Endocrinol Metab       Date:  2018-04-06       Impact factor: 3.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.